The effects of rosiglitazone on the neonatal rat cardiomyocyte transcriptome: a temporal analysis

Pharmacogenomics. 2019 Nov;20(16):1125-1141. doi: 10.2217/pgs-2019-0077.

Abstract

Aim: The objective was to determine via high-throughput RNA sequencing the temporal effects of rosiglitazone (Avandia®) on the neonatal rat ventricular myocyte transcriptome. Materials & methods: Neonatal rat ventricular myocytes (NRVMs) were exposed to rosiglitazone in vitro. Meta analyses utilized temporal comparisons of 0.5 h control versus 0.5 h treatment, 0.5 h treatment versus 24 h treatment and 24 h treatment versus 48 h treatment. Results: Time dependent responses were observed. At 0.5 h, the PI3K-AKT signaling pathway was impacted. At 24 h endoplasmic reticulum activity and protein degradation were altered. At 48 h, oxytocin signaling was perturbed. Conclusion: The effects of rosiglitazone occured early and increased in magnitude over time. A protective molecular response was triggered at 24 h and maintained until 48 h. In parallel, a response that can cause cardiac damage was activated. Our findings suggest that rosiglitazone has deleterious effects.

Keywords: Avandia®; RNAseq; Type 2 diabetes mellitus; neonatal rat ventricular myocytes; peroxisome proliferator-activated receptor-gamma; rosiglitazone.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Disease Models, Animal
  • Heart Ventricles / drug effects*
  • Heart Ventricles / pathology
  • Humans
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / pathology
  • Phosphatidylinositol 3-Kinases / genetics
  • Rats
  • Rosiglitazone / pharmacology*
  • Signal Transduction / drug effects
  • Transcriptome / drug effects
  • Transcriptome / genetics*

Substances

  • Rosiglitazone